Additive effect of diabetes mellitus on the prevalence and prognosis of sarcopenic obesity: Implications for all-cause mortality
- PMID: 40493627
- PMCID: PMC12151415
- DOI: 10.1371/journal.pone.0325423
Additive effect of diabetes mellitus on the prevalence and prognosis of sarcopenic obesity: Implications for all-cause mortality
Abstract
Diabetes mellitus (DM) and sarcopenic obesity are common conditions associated with increased morbidity and mortality. DM, characterized by chronic hyperglycemia, is a recognized risk factor for cardiovascular disease and premature death. Sarcopenic obesity, characterized by reduced muscle mass and increased adiposity, contributes to physical frailty and metabolic dysfunction. This study investigated the effect of DM on mortality rates and causes of death among individuals with high adiposity and low muscle mass (HA-LM) by using data from the National Health and Nutrition Examination Survey (NHANES) linked to mortality records from 2011 to 2018. A total of 2366 patients with HA-LM patients were analyzed, including 194 (8.199%) with DM and 2172 (91.80%) without DM. During the study period, the mortality rate was 1.19% in the HA-LM without DM group and 5.15% in the HA-LM with DM group. Kaplan-Meier survival analysis demonstrated a significantly higher mortality rate in the HA-LM patients with DM group, supported by both crude (hazard ratio [HR]: 4.34, 95% confidence interval [CI]: 2.09-9.00, p < 0.001) and adjusted (HR: 2.88, 95% CI: 1.23-6.73, p < 0.01) models. Cause-specific analysis revealed that heart disease (40%) was the leading cause of mortality in the HA-LM with DM group, followed by other residual causes (30%). By contrast, other residual causes were predominant among those without DM (34.62%), followed by malignant neoplasms (19.23%). These findings underscore the synergistic effects of DM and sarcopenic obesity on the risk of mortality and emphasize the need for targeted interventions aimed at managing diabetes and preserving muscle mass. The study findings may inform interventions aimed at improving health outcomes and reducing mortality in this high-risk population.
Copyright: © 2025 Kuo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures


Similar articles
-
Sarcopenia, sarcopenic obesity and mortality in older adults: results from the National Health and Nutrition Examination Survey III.Eur J Clin Nutr. 2014 Sep;68(9):1001-7. doi: 10.1038/ejcn.2014.117. Epub 2014 Jun 25. Eur J Clin Nutr. 2014. PMID: 24961545
-
A population-based approach to define body-composition phenotypes.Am J Clin Nutr. 2014 Jun;99(6):1369-77. doi: 10.3945/ajcn.113.078576. Epub 2014 Apr 23. Am J Clin Nutr. 2014. PMID: 24760978
-
Risks of All-Cause Mortality in Adults With Chronic Kidney Disease With Sarcopenia or Obesity: A Population-Based Study.J Cachexia Sarcopenia Muscle. 2025 Jun;16(3):e13828. doi: 10.1002/jcsm.13828. J Cachexia Sarcopenia Muscle. 2025. PMID: 40468984 Free PMC article.
-
Sarcopenia and sarcopenic obesity.Korean J Intern Med. 2016 Nov;31(6):1054-1060. doi: 10.3904/kjim.2016.193. Epub 2016 Nov 1. Korean J Intern Med. 2016. PMID: 27809450 Free PMC article. Review.
-
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management.Front Endocrinol (Lausanne). 2023 Jun 30;14:1185221. doi: 10.3389/fendo.2023.1185221. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37455897 Free PMC article. Review.
References
-
- Han H, Cao Y, Feng C, Zheng Y, Dhana K, Zhu S. Association of a healthy lifestyle with all-cause and cause-specific mortality among individuals with type 2 diabetes: a prospective study in UK Biobank. Diabetes Care. 2022. - PubMed
-
- Atkins JAO, Wannamathee SG. Sarcopenic obesity in ageing: cardiovascular outcomes and mortality. Br J Nutr. 2020. - PubMed
-
- Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020. - PubMed
-
- Faselis C, Katsimardou A, Imprialos K, Deligkaris P, Kallistratos M, Dimitriadis K. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical